Which GLP-1 drug will have the highest US market share by revenue on December 1, 2025?
3
125Ṁ40Dec 1
34%
Ozempic
17%
Wegovy
17%
Mounjaro
17%
Zepbound
17%
This question is managed and resolved by Manifold.
Get 
1,000 to start trading!
1,000People are also trading
Related questions
Will a drug company pay >$1m in a class action suit based on their statements about their GLP1 inhibitor by 2026?
38% chance
What fraction of US adults will regularly take GLP-1 drugs in 2030?
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
30% chance
Will an oral insulin pill be publicly available before the end of 2025?
24% chance
Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027
81% chance
Will one of the GLP agonist drugs (eg Semaglutude/Wegovy Tirzepatide/Mounjaro) have a black box warning by 2025
7% chance
Ozempic will NOT be the leading GLP-1 agonist by total $ US sales by December 31, 2025
42% chance
Will Ozempic/GLP-1 Agonists become an issue with a clear partisan divide in the US in the next 5 years?
45% chance
Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?
15% chance
Will a majority government owned company introduce a new GLP-1 drug before 2040?
15% chance